Brain volume loss due to donanemab.

Donanemab, an antibody directed toward an N-terminal pyroglutamate Aβ epitope, was recently tested in a phase 2 trial of early symptomatic Alzheimer's disease patients (n=257) treated for 76 weeks [1]. The antibody therapy reduced plaque load by 80%. This accompanied a significant (P=0.04) delay in decline (~6 month) in the integrated Alzheimer's Disease Rating Scale (iADRS) scale, but not 4 other cognitive/functional scales. However, donanemab treated patients had accelerated brain volume loss (~5ml) as assessed by MRI.